
In November, families have two things to keep track of. One is National Adoption Month, which includes a day of courthouse adoption ceremonies on November 21. The other is respiratory virus season, which is getting under way. For the 2026–2027 season, the American Academy of Pediatrics has widened the group of toddlers who qualify for a second RSV shot.
National Adoption Month and Key November Dates
National Adoption Month runs from Sunday, November 1, to Monday, November 30, 2026. The month highlights children in foster care who are waiting for permanent families.
Two dates fall inside the month. World Adoption Day is observed on November 9, and National Adoption Day falls on Saturday, November 21, 2026. On National Adoption Day, courthouses across the country hold ceremonies that finalize adoptions.
Families thinking about fostering or adopting can use the month as a starting point. A county court or local child welfare agency can say whether a ceremony is planned nearby.
RSV Protection for Babies This Season
Respiratory syncytial virus, or RSV, is a common cause of serious lung infections in infants. Since 2023, the CDC’s Advisory Committee on Immunization Practices has recommended RSV protection for all infants. There are two ways to do this. The mother can get an RSV vaccine during pregnancy, or the baby can get a long-acting antibody shot. Most infants do not need both.
Two antibody shots are available for infants under 8 months: clesrovimab (Enflonsia) and nirsevimab (Beyfortus). For both, the CDC lists October–March as the window for giving them. Clesrovimab is a single 105 mg (0.7 mL) dose at any weight. The nirsevimab dose depends on the baby’s weight: 50 mg (0.5 mL) for infants weighing <11 lb (<5 kg) and 100 mg for heavier babies.
The AAP does not prefer one licensed product over another when it suits the baby’s age and health.
When Newborns and Older Babies Should Get the Shot
Timing depends on when the baby was born:
- Born shortly before or during RSV season: within a week of birth, ideally before leaving the hospital.
- Birth hospital cannot give the shot: at a clinic as soon as it can be arranged.
- Under 8 months and born outside the season: just before RSV season starts, or as early in the season as possible.
Getting the shot does not mean a child can never catch RSV. A child can be reinfected, even within the same season.
What Changed for Toddlers in 2026–2027
The main change this year affects children in their second RSV season. Starting in the 2026–2027 season, the AAP added more medical conditions to the list that qualifies children 8 through 19 months old for a second shot. Children in this age group who are at high risk of severe RSV now qualify no matter whether the mother was vaccinated during pregnancy or whether the child got an antibody shot as a baby.
The second-season shot is limited to children who need it. The AAP limits second-season shots to children 8 through 19 months who meet its high-risk criteria. Nirsevimab is the only product recommended for this group.
Parents of toddlers with chronic health conditions can ask their pediatrician whether their child is on the expanded list. This is general information, not medical advice. The child’s doctor can say which option fits.
FAQ
– When is National Adoption Day in 2026?
It is on Saturday, November 21, 2026. Courthouses around the country hold ceremonies to finalize adoptions that day.
– Does my baby need an RSV shot if I got the RSV vaccine while pregnant?
Usually not. Most infants need either the maternal vaccine or an antibody shot, not both. However, high-risk toddlers entering their second season may now qualify no matter what their mother received.
– Is one RSV antibody shot better than the other?
The AAP does not prefer either one for infants under 8 months. For high-risk children in their second season, nirsevimab is the only product the CDC recommends.
Sources
- National Adoption Month 2026 — awarenessdays.com
- Recommendations for the Prevention of Respiratory Syncytial Virus Disease in Infants and Children: Policy Statement — publications.aap.org
- Use of Clesrovimab for Prevention of Severe Respiratory Syncytial Virus–Associated Lower Respiratory Tract Infections in Infants: Recommendations of the Advisory Committee on Immunization Practices — — cdc.gov
